Skip to main content
SpringerLink
Log in

Comorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment

  • Chapter
  • First Online:
Anxiety Disorders

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1191))

Abstract

Although anxiety and depression have been considered as two distinct entities according to the diagnostic criteria, anxious depression (comorbid anxiety and depression) is relatively a common syndrome. According to the DSM-5 criteria, it uses “with anxious distress specifier” to define anxious depression in its MDD section. Anxious depression is known to have different neurobiological profiles compared to non-anxious depression. Several studies have revealed significant differences between anxious depression and non-anxious depression regarding the hypothalamic-pituitary-adrenal (HPA) axis function, structural and functional brain imaging findings, inflammation markers, etc. Patients with anxious depression were significantly more likely to be found in primary care setting and more likely to be associated with female gender, non-single, unemployed, less educated, and more severe depression. Previous reports also showed that patients with anxious depression had more frequent episodes of major depression and a higher risk of suicidal ideation and previous suicide attempts than those with non-anxious depression. Although anxious depression is known to be associated with poor treatment outcomes in several studies, recent researches have sought to find better treatment strategy to improve patients with anxious depression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fava M, Alpert JE, Carmin CN, Wisniewski SR, Trivedi MH, Biggs MM, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR∗D. Psychol Med. 2004;34(7):1299–308.

    Article  PubMed  Google Scholar 

  2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–105.

    Article  PubMed  Google Scholar 

  3. Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJ, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands study of depression and anxiety (NESDA). J Clin Psychiatry. 2011;72(3):341–8.

    Article  PubMed  Google Scholar 

  4. Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, et al. Anxiety disorders in major depression. Compr Psychiatry. 2000;41(2):97–102.

    Article  CAS  PubMed  Google Scholar 

  5. Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol. 2001;110(4):585–99.

    Article  CAS  PubMed  Google Scholar 

  6. Rao S, Zisook S. Anxious depression: clinical features and treatment. Curr Psychiatry Rep. 2009;11(6):429–36.

    Article  PubMed  Google Scholar 

  7. Rush AJ. The varied clinical presentations of major depressive disorder. J Clin Psychiatry. 2007;68(Suppl 8):4–10.

    PubMed  Google Scholar 

  8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

    Book  Google Scholar 

  9. Wu Z, Chen J, Yuan C, Hong W, Peng D, Zhang C, et al. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. J Affect Disord. 2013;150(3):834–9.

    Article  PubMed  Google Scholar 

  10. Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, et al. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008;161(1):116–20.

    Article  CAS  PubMed  Google Scholar 

  11. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70.

    Article  PubMed  Google Scholar 

  12. Ionescu DF, Niciu MJ, Henter ID, Zarate CA. Defining anxious depression: a review of the literature. CNS Spectr. 2013;18(5):252–60.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Young EA, Abelson JL, Cameron OG. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol Psychiatry. 2004;56(2):113–20.

    Article  CAS  PubMed  Google Scholar 

  14. Kircanski K, LeMoult J, Ordaz S, Gotlib IH. Investigating the nature of co-occurring depression and anxiety: comparing diagnostic and dimensional research approaches. J Affect Disord. 2017;216:123–35.

    Article  PubMed  Google Scholar 

  15. Seo HJ, Jung YE, Kim TS, Kim JB, Lee MS, Kim JM, et al. Distinctive clinical characteristics and suicidal tendencies of patients with anxious depression. J Nerv Ment Dis. 2011;199(1):42–8.

    Article  PubMed  Google Scholar 

  16. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–51.

    Article  PubMed  Google Scholar 

  17. Ionescu DF, Niciu MJ, Mathews DC, Richards EM, Zarate CA Jr. Neurobiology of anxious depression: a review. Depress Anxiety. 2013;30(4):374–85.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991;100(3):316–36.

    Article  CAS  PubMed  Google Scholar 

  19. Davidson RJ. Anterior cerebral asymmetry and the nature of emotion. Brain Cogn. 1992;20(1):125–51.

    Article  CAS  PubMed  Google Scholar 

  20. Heller W, Etienne MA, Miller GA. Patterns of perceptual asymmetry in depression and anxiety: implications for neuropsychological models of emotion and psychopathology. J Abnorm Psychol. 1995;104(2):327–33.

    Article  CAS  PubMed  Google Scholar 

  21. Meller WH, Kathol RG, Samuelson SD, Gehris TL, Carroll BT, Pitts AF, et al. CRH challenge test in anxious depression. Biol Psychiatry. 1995;37(6):376–82.

    Article  CAS  PubMed  Google Scholar 

  22. Cameron OG. Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergic functions. Essent Psychopharmacol. 2006;7(1):24–34.

    PubMed  Google Scholar 

  23. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol. 2009;24(3):165–75.

    CAS  PubMed  Google Scholar 

  24. Rao ML, Vartzopoulos D, Fels K. Thyroid function in anxious and depressed patients. Pharmacopsychiatry. 1989;22(2):66–70.

    Article  CAS  PubMed  Google Scholar 

  25. van Tol MJ, van der Wee NJ, van den Heuvel OA, Nielen MM, Demenescu LR, Aleman A, et al. Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry. 2010;67(10):1002–11.

    Article  PubMed  Google Scholar 

  26. Inkster B, Rao AW, Ridler K, Nichols TE, Saemann PG, Auer DP, et al. Structural brain changes in patients with recurrent major depressive disorder presenting with anxiety symptoms. J Neuroimaging. 2011;21(4):375–82.

    Article  PubMed  Google Scholar 

  27. Etkin A, Schatzberg AF. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. Am J Psychiatry. 2011;168(9):968–78.

    Article  PubMed  Google Scholar 

  28. Waugh CE, Hamilton JP, Chen MC, Joormann J, Gotlib IH. Neural temporal dynamics of stress in comorbid major depressive disorder and social anxiety disorder. Biol Mood Anxiety Disord. 2012;2:11.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Andreescu C, Butters M, Lenze EJ, Venkatraman VK, Nable M, Reynolds CF 3rd, et al. fMRI activation in late-life anxious depression: a potential biomarker. Int J Geriatr Psychiatry. 2009;24(8):820–8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Andreescu C, Wu M, Butters MA, Figurski J, Reynolds CF 3rd, Aizenstein HJ. The default mode network in late-life anxious depression. Am J Geriatr Psychiatry. 2011;19(11):980–3.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hamilton JP, Chen MC, Waugh CE, Joormann J, Gotlib IH. Distinctive and common neural underpinnings of major depression, social anxiety, and their comorbidity. Soc Cogn Affect Neurosci. 2015;10(4):552–60.

    Article  PubMed  Google Scholar 

  32. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164(10):1476–88.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH. Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data. Am J Psychiatry. 2012;169(7):693–703.

    Article  PubMed  Google Scholar 

  34. Nelson BD, Sarapas C, Robison-Andrew EJ, Altman SE, Campbell ML, Shankman SA. Frontal brain asymmetry in depression with comorbid anxiety: a neuropsychological investigation. J Abnorm Psychol. 2012;121(3):579–91.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bruder GE, Fong R, Tenke CE, Leite P, Towey JP, Stewart JE, et al. Regional brain asymmetries in major depression with or without an anxiety disorder: a quantitative electroencephalographic study. Biol Psychiatry. 1997;41(9):939–48.

    Article  CAS  PubMed  Google Scholar 

  36. Manna CB, Tenke CE, Gates NA, Kayser J, Borod JC, Stewart JW, et al. EEG hemispheric asymmetries during cognitive tasks in depressed patients with high versus low trait anxiety. Clin EEG Neurosci. 2010;41(4):196–202.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.

    Article  CAS  PubMed  Google Scholar 

  38. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.

    Article  CAS  PubMed  Google Scholar 

  39. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139(3):230–9.

    Article  CAS  PubMed  Google Scholar 

  40. Vogelzangs N, de Jonge P, Smit JH, Bahn S, Penninx BW. Cytokine production capacity in depression and anxiety. Transl Psychiatry. 2016;6(5):e825.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Vogelzangs N, Beekman AT, de Jonge P, Penninx BW. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry. 2013;3:e249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Furtado M, Katzman MA. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 2015;229(1–2):37–48.

    Article  CAS  PubMed  Google Scholar 

  43. Liukkonen T, Rasanen P, Jokelainen J, Leinonen M, Jarvelin MR, Meyer-Rochow VB, et al. The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 birth cohort study. Eur Psychiatry. 2011;26(6):363–9.

    Article  CAS  PubMed  Google Scholar 

  44. Shim IH, Woo YS, Bahk WM. Associations between immune activation and the current severity of the "with anxious distress" specifier in patients with depressive disorders. Gen Hosp Psychiatry. 2016;42:27–31.

    Article  PubMed  Google Scholar 

  45. Baek JH, Kim HJ, Fava M, Mischoulon D, Papakostas GI, Nierenberg A, et al. Reduced venous blood basophil count and anxious depression in patients with major depressive disorder. Psychiatry Investig. 2016;13(3):321–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Gaspersz R, Lamers F, Wittenberg G, Beekman ATF, van Hemert AM, Schoevers RA, et al. The role of anxious distress in immune dysregulation in patients with major depressive disorder. Transl Psychiatry. 2017;7(12):1268.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. van der Linden MW, Huizinga TW, Stoeken DJ, Sturk A, Westendorp RG. Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. J Immunol Methods. 1998;218(1–2):63–71.

    Article  CAS  PubMed  Google Scholar 

  48. Fava M, Rush AJ, Alpert JE, Carmin CN, Balasubramani GK, Wisniewski SR, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006;51(13):823–35.

    Article  PubMed  Google Scholar 

  49. de Graaf R, Bijl RV, Smit F, Vollebergh WA, Spijker J. Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands mental health survey and incidence study. Am J Psychiatry. 2002;159(4):620–9.

    Article  PubMed  Google Scholar 

  50. Hovens JG, Wiersma JE, Giltay EJ, van Oppen P, Spinhoven P, Penninx BW, et al. Childhood life events and childhood trauma in adult patients with depressive, anxiety and comorbid disorders vs. controls. Acta Psychiatr Scand. 2010;122(1):66–74.

    Article  CAS  PubMed  Google Scholar 

  51. Kessler RC, Ormel J, Petukhova M, McLaughlin KA, Green JG, Russo LJ, et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry. 2011;68(1):90–100.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Klein DN, Glenn CR, Kosty DB, Seeley JR, Rohde P, Lewinsohn PM. Predictors of first lifetime onset of major depressive disorder in young adulthood. J Abnorm Psychol. 2013;122(1):1–6.

    Article  PubMed  Google Scholar 

  53. Fichter MM, Quadflieg N, Fischer UC, Kohlboeck G. Twenty-five-year course and outcome in anxiety and depression in the upper Bavarian longitudinal community study. Acta Psychiatr Scand. 2010;122(1):75–85.

    Article  CAS  PubMed  Google Scholar 

  54. Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry. 2000;176:229–35.

    Article  CAS  PubMed  Google Scholar 

  55. McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R. Overlap of anxiety and depression in a managed care population: prevalence and association with resource utilization. J Clin Psychiatry. 2006;67(8):1187–93.

    Article  PubMed  Google Scholar 

  56. Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al. Anxious and non-anxious major depressive disorder in the World Health Organization world mental health surveys. Epidemiol Psychiatr Sci. 2015;24(3):210–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Baek JH, Heo JY, Fava M, Mischoulon D, Nierenberg A, Hong JP, et al. Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. J Affect Disord. 2015;187:183–7.

    Article  PubMed  Google Scholar 

  58. McIntyre RS, Woldeyohannes HO, Soczynska JK, Vinberg M, Cha DS, Lee Y, et al. The prevalence and clinical characteristics associated with diagnostic and statistical manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the international mood disorders collaborative project. Ther Adv Chronic Dis. 2016;7(3):153–9.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR∗D trial. J Clin Psychiatry. 2014;75(7):738–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Saveanu R, Etkin A, Duchemin AM, Goldstein-Piekarski A, Gyurak A, Debattista C, et al. The international study to predict optimized treatment in depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015;61:1–12.

    Article  PubMed  Google Scholar 

  61. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. Am J Psychiatry. 2008;165(3):342–51.

    Article  PubMed  Google Scholar 

  62. Domschke K, Deckert J, Arolt V, Baune BT. Anxious versus non-anxious depression: difference in treatment outcome. J Psychopharmacol. 2010;24(4):621–2.

    Article  CAS  PubMed  Google Scholar 

  63. Altamura AC, Montresor C, Salvadori D, Mundo E. Does comorbid subthreshold anxiety affect clinical presentation and treatment response in depression? A preliminary 12-month naturalistic study. Int J Neuropsychopharmacol. 2004;7(4):481–7.

    Article  PubMed  Google Scholar 

  64. Clayton PJ, Grove WM, Coryell W, Keller M, Hirschfeld R, Fawcett J. Follow-up and family study of anxious depression. Am J Psychiatry. 1991;148(11):1512–7.

    Article  CAS  PubMed  Google Scholar 

  65. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000;59(2):119–26.

    Article  CAS  PubMed  Google Scholar 

  66. Feiger AD, Flament MF, Boyer P, Gillespie JA. Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies. Int Clin Psychopharmacol. 2003;18(4):203–10.

    Article  PubMed  Google Scholar 

  67. Papakostas GI, Fan H, Tedeschini E. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol. 2012;22(5):347–55.

    Article  CAS  PubMed  Google Scholar 

  68. Nasso ED, Chiesa A, Serretti A, De Ronchi D, Mencacci C. Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. Clin Drug Investig. 2011;31(6):385–405.

    Article  PubMed  Google Scholar 

  69. Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry. 2007;19(3):187–95.

    Article  PubMed  Google Scholar 

  70. Nelson JC. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression. J Clin Psychopharmacol. 2011;31(5):682–4.

    Article  PubMed  Google Scholar 

  71. Akkaya C, Sivrioglu EY, Akgoz S, Eker SS, Kirli S. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. Hum Psychopharmacol. 2006;21(5):337–45.

    Article  CAS  PubMed  Google Scholar 

  72. Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim Care Companion J Clin Psychiatry. 2008;10(3):222–8.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998;155(10):1339–45.

    Article  CAS  PubMed  Google Scholar 

  74. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008;69(8):1287–92.

    Article  CAS  PubMed  Google Scholar 

  75. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16(1):4–13.

    Article  CAS  PubMed  Google Scholar 

  76. Sir A, D’Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66(10):1312–20.

    Article  CAS  PubMed  Google Scholar 

  77. Papakostas GI, Larsen K. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci. 2011;261(3):147–56.

    Article  PubMed  Google Scholar 

  78. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826–31.

    Article  CAS  PubMed  Google Scholar 

  79. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–91.

    Article  PubMed  Google Scholar 

  80. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574–86.

    Article  CAS  PubMed  Google Scholar 

  82. Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008;69(12):1928–36.

    Article  CAS  PubMed  Google Scholar 

  83. Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, et al. Ziprasidone augmentation for anxious depression. Int Clin Psychopharmacol. 2016;31(6):341–6.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiat. 2017;74(4):399–405.

    Article  Google Scholar 

  85. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932–8.

    Article  CAS  PubMed  Google Scholar 

  86. Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, et al. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019;36(3):235–43.

    Article  CAS  PubMed  Google Scholar 

  87. Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36(3):195–206.

    Article  CAS  PubMed  Google Scholar 

  88. Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, et al. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology (Berl). 2016;233(6):1119–30.

    Article  CAS  Google Scholar 

  89. Thase ME, Weiller E, Zhang P, Weiss C, McIntyre RS. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat. 2019;15:37–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Korea University College of Medicine, Seoul, South Korea

    Kwan Woo Choi & Yong-Ku Kim

  2. Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Kwan Woo Choi & Hong Jin Jeon

Authors
  1. Kwan Woo Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong-Ku Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Jin Jeon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Jin Jeon .

Editor information

Editors and Affiliations

  1. College of Medicine, Korea University, Gyeonggido, Korea (Republic of)

    Yong-Ku Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Choi, K.W., Kim, YK., Jeon, H.J. (2020). Comorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment. In: Kim, YK. (eds) Anxiety Disorders. Advances in Experimental Medicine and Biology, vol 1191. Springer, Singapore. https://doi.org/10.1007/978-981-32-9705-0_14

Download citation

Publish with us

Policies and ethics

Search

Navigation